Scarica l'app Stockscreener
0.00
100.00%
-123.96
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NUVL Giù?
Forum
Previsione
Precedente Chiudi:
$123.96
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$9.81B
Reddito:
-
Utile/perdita netta:
$-450.07M
Rapporto P/E:
0.00
EPS:
-6.0583
Flusso di cassa netto:
$-312.79M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$123.99
Nuvalent Inc Stock (NUVL) Company Profile
Nome
Nuvalent Inc
Settore
Industria
Telefono
508-446-2272
Indirizzo
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
0.00 | 9.81B | 0 | -450.07M | -312.79M | -6.0583 |
VRTX
Vertex Pharmaceuticals Inc
|
519.51 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.74 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.54 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
146.69 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
205.11 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-06-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2026-05-22 | Iniziato | Bernstein | Outperform |
| 2026-03-30 | Iniziato | Wells Fargo | Overweight |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-12 | Iniziato | Canaccord Genuity | Buy |
| 2025-10-16 | Ripresa | Stifel | Buy |
| 2025-10-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-09-03 | Iniziato | Raymond James | Outperform |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-03-14 | Aggiornamento | UBS | Neutral → Buy |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-24 | Iniziato | UBS | Neutral |
| 2024-08-29 | Iniziato | Barclays | Overweight |
| 2024-04-17 | Iniziato | Jefferies | Buy |
| 2024-04-01 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Ripresa | Guggenheim | Buy |
| 2024-02-23 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-27 | Iniziato | Stifel | Buy |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-24 | Iniziato | Guggenheim | Buy |
| 2023-01-18 | Iniziato | Wedbush | Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
Mostra tutto
Nuvalent Inc Borsa (NUVL) Ultime notizie
NUVL Stock Surges 39% Premarket – Why Is GSK Buying This Boston-Based Oncology Company? - Stocktwits
GSK to Raise $6.5 Billion From US Debt Sale to Fund Nuvalent Acquisition - marketscreener.com
GSK to Raise $6.5 Billion From US Debt Sale to Fund Nuvalent Acquisition, Bloomberg Reports - marketscreener.com
GSK Commences Six-Part Dollar Bond Sale to Help Fund Nuvalent Acquisition - marketscreener.com
GSK Launches Six-Part Dollar Bond Sale to Support Nuvalent Acquisition Financing, Bloomberg Reports - marketscreener.com
Nuvalent, Inc. (NUVL) Stock Analysis: What Investors Need to Know About This $9.81 Billion Biotech Player - DirectorsTalk Interviews
Deerfield Management Announces Portfolio Company Nuvalent, Inc. to be Acquired by GSK - Eastern Progress
Nuvalent, Inc. (NUVL) Stock Analysis: Exploring the Biotech’s Steady Path with a $9.81 Billion Market Cap - DirectorsTalk Interviews
Nuvalent, Inc. (NUVL) Stock Analysis: Evaluating Growth Potential Amidst a Steady Market Position - DirectorsTalk Interviews
Nuvalent (NUVL) Results Review: EPS Does Not Reach the Reported Estimate in the Latest Reading; Latest Reaction: The Immediate Price Response Is Limited for the Current SessionEarnings Deceleration Risk - vinanet.vn
Nuvalent Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
Nuvalent, Inc. (NUVL) Stock Analysis: Steady at $123.96 with Phase 2 Clinical Trials on the Horizon - DirectorsTalk Interviews
Nuvalent, Inc. (NUVL) Stock Analysis: Navigating Biotech’s Uncharted Waters with Zero Upside - DirectorsTalk Interviews
Equity in earnings of Nuvalent, Inc. Class A – LS:A3CWDU - TradingView
Nuvalent Inc (NUVL) Stock Analysis & Forecast - TradingKey
Nuvalent Inc (NUVL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enterprise value to EBIT forward of Nuvalent, Inc. Class A – LS:A3CWDU - TradingView
Nuvalent, Inc. (NUVL) Stock Analysis: A $9.79 Billion Biotech Game-Changer Facing Analyst Consensus - DirectorsTalk Interviews
Nuvalent Inc (NUVL) Institutional Confidence - TradingKey
Nuvalent, Inc. SEC Filing (Jul 27, 2026) - Stock Titan
Nuvalent Inc (NUVL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NUVL|Nuvalent Inc|Price:123.965| - TradingKey
Nuvalent Inc (NUVL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nuvalent Inc (NUVL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nuvalent Inc (NUVL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nuvalent Inc (NUVL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Nuvalent Inc (NUVL) Cash Flow - TradingKey
Nuvalent, Inc. Class A Revenue Breakdown – LS:A3CWDU - TradingView
GSK Lands Its First Lung Cancer Drug Days After Nuvalent Deal Closes - finance.biggo.com
FDA Approves NSCLC Treatment Acquired by GSK in Nuvalent Deal - Contract Pharma
GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet - Yahoo Finance
GSK Lands FDA Approval for Nuvalent-Acquired Jideytro for NSCLC - Yahoo Finance
A Quick Look at Today's Ratings for Nuvalent(NUVL.US), With a Forecast Between $116 to $155 - Moomoo
GSK's $10.6B Nuvalent acquisition delivers first FDA approval ahead of schedule - The Business Journals
GSK secures first lung cancer approval as FDA clears Jideytro in quick payoff from Nuvalent deal - Fierce Pharma
Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer - PR Newswire
Bernstein initiates coverage of Nuvalent (NUVL) with outperform recommendation - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasd - Supply Chain Digital
How Nuvalent Inc. (NUVL) Affects Rotational Strategy Timing - Stock Traders Daily
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Wall Street Zen Upgrades Nuvalent (NASDAQ:NUVL) to Sell - MarketBeat
Deerfield group reports 0% ownership in Nuvalent (NUVL) Class A shares - Stock Titan
Deerfield holders cash out of Nuvalent (NUVL) at $124 per share - Stock Titan
Nuvalent, Inc.(NasdaqGM: ) dropped from Russell 2500 Growth Index - marketscreener.com
Halper Sadeh LLC is Investigating Whether ATAI, CCRN, NUVL are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Nuvalent, Inc.(NasdaqGM: ) dropped from Russell 2000 Defensive Index - marketscreener.com
Form 4 Nuvalent Inc For: 15 July By Investing.com - Investing.com Canada
Nuvalent, Inc. (NUVL) director exits holdings in $124 GSK merger - Stock Titan
Nuvalent, Inc. (NUVL) CFO details tender offer and award cash-outs - Stock Titan
Form 4 Nuvalent Inc For: 15 July - Investing.com India
Nuvalent, Inc. (NUVL) director tenders stock in $124 GSK cash buyout - Stock Titan
Nuvalent Inc Azioni (NUVL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.75%
3.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):